General Information of Drug (ID: DM6XWV4)

Drug Name
EGFRvIII CAR T cells Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma multiforme 2A00.0 Phase 1 [1]
Recurrent glioblastoma 2A00.00 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM6XWV4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anti-EGFRvIII CAR transduced PBL DMDKTYU Brain cancer 2A00 Phase 1/2 [2]
EGFRvIII CAR DMC284G Glioblastoma multiforme 2A00.0 Phase 1/2 [3]
Anti-EGFR V III CAR-T cells DM8EAGV Glioma 2A00.0 Phase 1/2 [4]
AMG 596 DM4G1SP Glioblastoma multiforme 2A00.0 Phase 1 [5]
D2C7 DMIMK84 Glioblastoma of brain 2A00.00 Phase 1 [6]
CAR-T cells targeting EGFRviii DMRSG04 Glioblastoma multiforme 2A00.0 Phase 1 [7]
Anti-EGFRvIII CAR T cells DM73920 Glioblastoma multiforme 2A00.0 Phase 1 [8]
CART-EGFRvIII T cells DMGPR1C Recurrent glioblastoma 2A00.00 Phase 1 [9]
EGFRvIII-CARs DMA46RN Recurrent glioblastoma 2A00.00 Phase 1 [10]
CAR-T cells targeting EGFRviii DMRSG04 Glioblastoma multiforme 2A00.0 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor variant III (EGFR vIII) TTZ6B2I EGFR_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
2 ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
3 EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
4 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
5 Clinical pipeline report, company report or official report of Amgen.
6 Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
7 ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
8 ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
9 ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
10 ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
11 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.